This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458508097299v1 15/2/219    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Giovannoni, G Articles by Stubinski, B Search for Related Content PubMed PubMed Citation Articles by Giovannoni, G Articles by Stubinski, B Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Safety and immunogenicity of a new formulation of interferon -1a (Rebif^® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

¹ Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK
² State Educational Institute of Higher Professional Education, Kemerovo State Medical Academy, Kemerovo, Russia
³ Merck Serono International S.A.*, Geneva, Switzerland
⁴ Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia
⁵ Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
⁶ MS Center of Oklahoma, Mercy NeuroScience Institute, Oklahoma City, Oklahoma, USA
⁷ Neurology Center of Fairfax, Hamaker Ct Ste 400, Fairfax, Virginia, USA
⁸ Department of Neurology, Danish MS Research Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

^* To whom correspondence should be addressed.

	Abstract

Background

A new formulation of subcutaneous (s.c.) interferon--1a has been developed (Rebif^® New Formulation, RNF), produced without fetal bovine serum and without human serum albumin as an excipient, with the aim of improving injection tolerability, and reducing immunogenicity.

Objectives

This article reports 96-week analyses of a Phase IIIb, open-label study of the safety and immunogenicity of RNF compared with historical (EVIDENCE study) and recent (REGARD study) data on the original formulation.

Methods

Patients with relapsing multiple sclerosis (McDonald criteria) and an Expanded Disability Status Scale score < 6.0 received RNF, 44 µg s.c. three times weekly.

Results

The proportion of neutralizing antibody-positive (NAb+) patients (serum NAb status 20 neutralizing units/mL) at week 96 (last observation carried forward; primary endpoint) was 17.4% (exact 95% confidence interval [CI]: 13.0–22.5), compared with 21.4% (95% CI: 17.2–26.2) in the EVIDENCE study, and 27.3% (95% CI: 22.8–32.1) in the REGARD study. The proportion of patients NAb+ at any time during the 96 weeks was 18.9% (95% CI: 14.4–24.2), compared with 27.1% (95% CI: 22.4–32.2) and 33.7% (95% CI: 28.9–38.7), respectively. Most pre-specified categories of adverse events were reported by patients in the RNF study at a similar or lower proportion than in the EVIDENCE and REGARD studies. Injection-site reactions were experienced by fewer patients than in the EVIDENCE and REGARD studies.

Conclusions

RNF has improved overall immunogenicity and safety profiles compared with the original formulation.

Key Words: immunogenicity, injection-site reactions, interferon--1a, multiple sclerosis, Rebif^® New Formulation, safety

First published on August 28, 2008, doi:10.1177/1352458508097299

Multiple Sclerosis 2009;15:219.

A more recent version of this article appeared on February 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?